About Us
About Noxopharm
CEO's Message
Management Team
Board of Directors
Scientific Advisors
Our Network
Pharmorage
ESG Commitment
Technology
Technology Platforms
Sofra™
RNA Vaccines and Therapeutics
Autoimmune Disease
Scientific Background
Chroma™
Clinical Trials
Publications & Events
Investor Centre
Share Price
ASX Announcements
Presentations, Interviews & Media
Annual Reports
Financial Reports
Corporate Governance
Investor Fact Sheet
Share Registry Information
Contact Us
Contact Us
Partnering
Working at Noxopharm
ASX Announcements Email Alerts
Investor Centre
Investor Centre
>
Presentations, Interviews & Media
Share Price
ASX Announcements
Presentations, Interviews & Media
Annual Reports
Financial Reports
Corporate Governance
Investor Fact Sheet
Share Registry Information
Presentations, Interviews & Media
Filter by Year:
2026
2025
2024
2023
2022
22-Apr-2026
Noxopharm flags prolonged skin retention data for SOF-SKN as it moves toward human trial | ASX:NOX
21-Apr-2026
Noxopharm appoints Dr Olivier Laczka as Chief Executive Officer | BioMelbourne Network
13-Feb-2026
Noxopharm says paper reveals science behind its immune system platform
10-Feb-2026
Tiny one- to three-base RNAs could help stop autoimmune inflammation, study suggests
10-Feb-2026
Tiny RNA fragments unlock massive autoimmune treatment potential - Hudson Institute of Medical Research
1
